← Back to Search

Polyamine Synthesis Inhibitor

Treatment for Neuroblastoma

N/A
Waitlist Available
Research Sponsored by Giselle Sholler
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

Eligible Conditions
  • Neuroblastoma
  • Medulloblastoma
  • Teratoid Rhabdoid Tumor
  • Ependymoblastoma
  • Medulloepithelioma
  • Embryonal Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Giselle ShollerLead Sponsor
22 Previous Clinical Trials
2,490 Total Patients Enrolled
19 Trials studying Neuroblastoma
1,863 Patients Enrolled for Neuroblastoma
Wake Forest University Health SciencesLead Sponsor
1,361 Previous Clinical Trials
1,040,009 Total Patients Enrolled
19 Trials studying Neuroblastoma
1,835 Patients Enrolled for Neuroblastoma
K C Pharmaceuticals Inc.Industry Sponsor
4 Previous Clinical Trials
787 Total Patients Enrolled
4 Trials studying Neuroblastoma
787 Patients Enrolled for Neuroblastoma
~233 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top